Drug intelligence / Profile preview

MNF

Development stage: Unknown
Lead developer: Bal Pharma
Modality: Small Molecules
Administration: Oral

Overview

**MNF** is a marketed Bal Pharma oral nutritional-supplement product line, represented by MNF tablets containing essential amino acids, multivitamins, folic acid, vitamin C, vitamin B6, vitamin B12, and zinc. It is used to address nutritional deficiencies and support protein synthesis, tissue repair, immune function, energy metabolism, and general health. The MNF tablet formulation is a multi-ingredient fixed-dose nutritional product rather than a single active pharmaceutical ingredient. ([balpharma.com](https://www.balpharma.com/domestic))

Brand names: MNF

Targets

ADRB2 (β2)GPR55 (G protein-coupled receptor 55)

Beyond the preview

Go deeper on MNF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MNF.

Explore the full profile